Altogether, allocating $4,000 into these four healthcare stocks on the TSX offers a balanced approach to investing in a sector that combines stability with growth potential. Each company presents ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Cipher Pharmaceuticals Inc (CPHRF) reports a remarkable 141% increase in net revenue, driven by strategic acquisitions and robust product performance.

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

In Q3 of 2024, Cipher Pharmaceuticals (TSX:CPH) reported a 71% increase in revenue, with sales rising to $10.4 million. The growth was primarily driven by its late July acquisition of Natroba.

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology.